BiotechTube

KVD900

Phase 2Completed
0 watching 0 views this week⚡ Active
47
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Hereditary Angioedema

Conditions

Hereditary Angioedema

Trial Timeline

Jul 2, 2019 → Dec 8, 2020

NCT ID
NCT04208412

About KVD900

KVD900 is a phase 2 stage product being developed by KalVista Pharmaceuticals for Hereditary Angioedema. The current trial status is completed. This product is registered under clinical trial identifier NCT04208412. Target conditions include Hereditary Angioedema.

Hype Score Breakdown

Clinical
17
Activity
12
Company
5
Novelty
5
Community
5

Clinical Trials (1)

NCT IDPhaseStatus
NCT04208412Phase 2Completed

Competing Products

20 competing products in Hereditary Angioedema

See all competitors
ProductCompanyStageHype Score
KVD824 + Placebo to KVD824KalVista PharmaceuticalsPhase 1
28
KVD900 600 mg + KVD900 300 mgKalVista PharmaceuticalsPhase 3
72
SebetralstatKalVista PharmaceuticalsPre-clinical
18
KVD900 + Placebo to KVD900KalVista PharmaceuticalsPhase 1
28
SebetralstatKalVista PharmaceuticalsPre-clinical
18
Placebo + KVD900 600 mg + KVD900 300 mgKalVista PharmaceuticalsPhase 3
72
KVD824 Prototype 1 modified-release tablet + KVD824 Prototype 2 modified-release tablet + KVD824 Immediate-Release Capsule + Placebo to KVD824 Prototype 1 + KVD824 Prototype 3 modified-release tabletKalVista PharmaceuticalsPhase 1
28
KVD900 150 mg + KVD900 300 mg + KVD900 600 mgKalVista PharmaceuticalsPhase 3
72
KVD824 + Placebo to KVD824KalVista PharmaceuticalsPhase 2
47
KVD900 600 mg + Drug: KVD900 300 mgKalVista PharmaceuticalsPhase 3
72
Deferasirox FCTNovartisPhase 2
52
Canakinumab + PlaceboNovartisPhase 3
77
IlarisNovartisPre-clinical
23
Standard of Care for Haemophilia ARochePre-clinical
23
EmicizumabRochePhase 3
77
TafamidisPfizerPre-clinical
22
tafamidisPfizerPre-clinical
22
NitisinoneSwedish Orphan BiovitrumPre-clinical
22
NitisinoneSwedish Orphan BiovitrumPhase 1
32
NitisinoneSwedish Orphan BiovitrumPre-clinical
22

Other Products from KalVista Pharmaceuticals

Placebo + KVD900 600 mg + KVD900 300 mgPhase 3
72
KVD900 600 mg + Drug: KVD900 300 mgPhase 3
72
KVD900 600 mg + KVD900 300 mgPhase 3
72
KVD900 150 mg + KVD900 300 mg + KVD900 600 mgPhase 3
72
KVD824 + Placebo to KVD824Phase 2
47